MARKET

IMRX

IMRX

Immuneering Corp
NASDAQ
6.73
-0.08
-1.17%
After Hours: 6.86 +0.13 +1.93% 19:47 12/26 EST
OPEN
6.84
PREV CLOSE
6.81
HIGH
6.87
LOW
6.57
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
1.100
MARKET CAP
434.56M
P/E (TTM)
-3.7745
1D
5D
1M
3M
1Y
5Y
1D
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
Benzinga · 3d ago
Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial
NASDAQ · 3d ago
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP
TipRanks · 4d ago
Immuneering To Provide 12-Month Overall Survival From Its Current Phase 2a Clinical Study Of Atebimetinib + Modified Gemcitabine In Pancreatic Participants
Benzinga · 4d ago
Immuneering to Announce 12-Month Survival Data from Phase 2a Pancreatic Cancer Trial
Reuters · 4d ago
IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON JANUARY 7, 2026
Reuters · 4d ago
Weekly Report: what happened at IMRX last week (1215-1219)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: PACS Group Inc (PACS), Novan (NOVN) and Immuneering (IMRX)
TipRanks · 12/18 11:10
More
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Webull offers Immuneering Corp stock information, including NASDAQ: IMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMRX stock methods without spending real money on the virtual paper trading platform.